1. Introduction {#sec0005}
===============

People who use illicit opioids such as heroin have high rates of mortality and morbidity, with an age-standardised mortality risk of between four and 15 times the general population ([@bib0015]). In England, people identified as dependent on opiates by drug treatment and criminal justice services have a six-fold increased risk of death ([@bib0080]). There are fewer studies of morbidity in this population, with most focusing on blood borne viral infections and mental health problems ([@bib0005]).

Although drug overdose is often found to be the largest single cause of death among people who are dependent on illicit drugs, it usually accounts for less than half of deaths overall ([@bib0015]; [@bib0030]; [@bib0080]). Available data suggests cardiovascular disease, respiratory disease, and liver disease also cause many deaths among people who use drugs, and account for an increasing proportion as age increases ([@bib0020]; [@bib0045]; [@bib0080]). Although these conditions are common in the general population, their contribution to excess morbidity and mortality among people who use illicit drugs is unclear.

People who are dependent on illicit drugs have extremely high relative risks of overdose, hepatitis C, HIV and mental health problems. Some diseases have become specifically associated with illicit drug use, including hepatitis C in many high income countries. Treatment and harm reduction initiatives to improve health among people who use drugs have focused on these areas. In contrast, conditions such as cardiovascular disease, which may cause greater absolute morbidity and mortality yet have lower relative risks because they are common in the general population, have received less attention. Due to the frequent disparities between relative and absolute risks in epidemiological studies, the STROBE guidelines for reporting of observational studies recommend reporting both where possible ([@bib0095]). However, few studies actually do this ([@bib0040]).

To address this, we have used data from a large cohort of people in treatment for heroin dependence to compare relative and absolute risks of hospital admission (as a proxy for morbidity) and death across a range of disease categories, and reported excess morbidity and mortality in this cohort.

2. Materials and methods {#sec0010}
========================

We used data from the Clinical Records Interactive Search resource at the South London and Maudsley NHS Foundation Trust Biomedical Research Centre. This is a research repository of anonymised records derived from the electronic health record system of a mental healthcare provider in South London, England ([@bib0075]). The study population was 6833 patients aged 18--64 entering community-based treatment for heroin dependence between 1 January 2006 and 31 March 2017. Patients were linked using NHS number, date of birth, sex and postcode to inpatient hospital admissions data from the national Hospital Episode Statistics for England database, and to mortality data from the Office for National Statistics. Linkage was conducted by NHS Digital, a public sector statistical agency. Linkage for hospital admissions was conducted until 31 March 2017 and for mortality until 31 January 2019. Some patients have long periods of engagement with the drug treatment service, while other only attend one appointment, but data linkage was available for all patients regardless of their engagement with the service.

To allow calculation of reference rates for the general population, we also accessed hospital admission data for all residents in the healthcare provider's catchment area of the London Boroughs of Croydon, Lambeth, Lewisham and Southwark, and the number of deaths by age group, sex and cause for all residents of London from the Office for National Statistics. Denominators for the relevant general populations were derived from publicly available population estimates ([@bib0065]). The reference data were accessed for 2006--2016 as the closest available match to the study cohort.

For descriptive purposes, we reported drug use according to standard National Drug Treatment and Monitoring System (NDTMS, [@bib0090]) forms collected by the service provider. These data are collected for each patient at entry to the service, treatment reviews and at discharge. We identified patients as heroin users where heroin was listed on any NDTMS form collected during the study period. Poly-drug use is common in this cohort and we also reported other drugs that were listed for at least 10% of patients. Where any NDTMS form listed 'currently injecting', we classified the patient as 'reported injecting during the study'.

2.1. Disease categories {#sec0015}
-----------------------

We used a two-level hierarchy to classify deaths. First, we grouped deaths according to the ICD-10 chapter ([@bib0100]) of the underlying cause of death (such as 'respiratory diseases'). Chapters with fewer than 10 deaths during the study period were grouped together under 'other'. Second, we grouped deaths according to three-character subcategories (such as 'influenza and pneumonia'), again grouping subcategories with fewer than 10 deaths under 'other'. We used a similar process to group hospital admissions, classifying admissions based on the primary diagnosis and classifying categories with fewer than 250 admissions under 'other'. For both mortality and hospital admissions, we separated out 'drug-related' events, using the Office for National Statistics definition ([@bib0060]) (see Supplementary Material). This identified events where the main cause related directly to the use of illicit drugs. In the mortality data, these events are most commonly overdoses, and are more diverse for hospitalisations, including intoxication and drug withdrawal.

2.2. Calculation of relative and absolute risks {#sec0020}
-----------------------------------------------

We calculated reference rates for death and hospital admission in the general population within sex and age groups (18--24, 25--34, 35--44, 45--54 and 55--64) for each disease. We then calculated the expected numbers of events by applying these reference rates to the study population, with time-at-risk calculated for each stratum and accounting for individuals aging during the study. We calculated standardised mortality ratios (SMRs) and standardised admission ratios (SARs) by dividing observed events by expected events (i.e. indirect standardisation). Excess events were calculated as the observed minus the expected events. A formula for calculating the excess events is provided in the Supplementary Material, together with a worked example including analysis code.

We calculated 95% confidence intervals using the exact poisson method ([@bib0035]). We also used the Kaplan-Meier method to estimate the risk of all-cause death over ten years.

All analyses were conducted using R version 3.5.1.

3. Results {#sec0025}
==========

3.1. Cohort characteristics {#sec0030}
---------------------------

Most patients were aged 25--44 and three-quarters were male, reflecting the demographics of patients entering treatment for opiate dependence nationally ([@bib0090]). The majority of patients (72%) used crack cocaine as well as heroin. Use of alcohol, cannabis, and benzodiazepines was also recorded for more than 10% of patients. One in three reported injecting during follow-up, though this is likely to be a lower-bound because patients may not want to disclose injecting while they are prescribed opiate substitution therapy. The cohort characteristics are summarised in [Table 1](#tbl0005){ref-type="table"}.Table 1Cohort characteristics for 6683 people who use heroin.Table 1VariableLevelNumber of participants (%)Age at first treatment episode18--25552 (8)25--342259 (34)35--442568 (38)45--541099 (16)55--64205 (3)SexFemale1727 (26)Male4956 (74)EthnicityWhite5260 (79)Black803 (12)Mixed212 (3)Asian204 (3)Other/unknown204 (3)Other drugsCrack cocaine4813 (72)Alcohol2961 (44)Cannabis1628 (24)Benzodiapines747 (11)Reported injecting during the studyYes2335 (35)No4348 (65)**Total6683 (100)**

3.2. Mortality {#sec0035}
--------------

During 55,639 years of follow-up (median 9.4, range 0--13), there were 732 deaths, giving a crude all-cause mortality rate of 132/10,000 person-years and an SMR of 6.6 (95% CI 6.1--7.1). There were 621 excess deaths (95% CI 569--676). A Kaplan-Meier estimate suggested that 12.6% (95% CI 11.7%--13.5%) of patients would have died after 10 years of follow-up, with 2800 remaining in the risk set.

Of the 621 excess deaths, 260 (42%) were drug-related and 361 (58%) were due to other causes. The SMRs were 48 (95% CI 42--54) for drug-related deaths and 4.4 (95% CI 4.0--4.9) for all other causes combined. Among ICD-10 chapters, digestive diseases caused the most excess deaths (97), followed by respiratory disease (58) and external causes (46). The largest subcategories were liver disease (75), COPD (45) and accidents (30). The number of deaths and excess deaths are summarised in [Fig. 1](#fig0005){ref-type="fig"}, with full results are given in Supplementary Material, including comparisons to existing studies.Fig. 1Number of deaths and hospital admissions in a cohort of 6683 people who use heroin in South London, 2016--2019. The area of the circles is proportional to the number of events, while the dark sections show the number of excess events.Fig. 1

3.3. Hospital admissions {#sec0040}
------------------------

During 44,590 years of follow-up (median 7.7, range 0--11), there were 21,494 hospital admissions, giving a crude admission rate of 482/1,000 person-years and a SAR of 3.15 (95% CI 3.11--3.19). There were 14,668 excess admissions (95% CI 14,382--14,957).

Of the 14,668 excess admissions, 3042 (20.7%) were drug-related and 11,790 (80.3%) were primarily related to other causes. The SARs were 293 (95% CI 282--304) for drug-related admissions and 2.77 (95% CI 2.73--2.81) for all other causes. Among ICD-10 chapters, mental and behavioural disorders caused the most excess admissions (2055), followed by digestive diseases (1940) and external causes (1685). The largest subcategories were mental and behavioural disorders due to alcohol (1060 excess admissions), COPD (812), head injury (612), and diseases of the oral cavity, predominantly dental caries (516).

4. Discussion {#sec0045}
=============

We conducted a population-based cohort study of people who use heroin and had at least one contact with community-based drug treatment services. Consistent with existing studies of similar populations, our cohort had extreme risk of hospitalisation and death. The majority of excess morbidity and mortality in this population related to common non-communicable diseases.

The use of 'excess events' shows the breadth of important diseases in this group, in contrast to the use of relative risks alone, which prioritise drug-related events, blood-borne viruses and mental health problems. The analysis of mortality highlights the importance of digestive, respiratory and cardiovascular diseases, and external causes such as accidents. The analysis of hospital admissions shows that the excess burden of non-communicable diseases is four times greater than for drug-related conditions, and particularly highlights the importance of liver disease, COPD, dental caries and head injuries. Although we provide a more detailed break-down than previous studies, our results are broadly consistent with existing research ([@bib0045], [@bib0050]; [@bib0080]). The literature on health inequalities generally focuses on relative risks, with few studies reporting both relative and absolute risks ([@bib0040]). Our results provide an example of the radically different effects when relative and absolute risks are compared.

We used a linkage system with national mortality and hospital databases, which is important because the study population is likely to be mobile and local databases underestimate the rate of events. A limitation of the analysis is that hospital admissions capture a severe aspect of morbidity, and further research should examine primary care data to provide a more detailed picture. Our data included information on a range of drugs recorded by the drug treatment service, but did not provide detailed information on routes of administration. Three-quarters of patients used both heroin and crack cocaine, but the data does not show whether patients used these drugs separately or mixed them together as 'speedballs'.

The mortality and hospital admission results showed some different patterns. For example, patients in our cohort were twice as likely to die due to cancer compared to the general population, but were half as likely to be admitted to hospital for cancer treatment. The lower-than-expected rate of hospital admission related to cancer has also been observed for opiate users in Scotland ([@bib0045]). The reasons for this are not clear, but may relate to poorer diagnosis of cancer among people who use heroin, or delayed help-seeking when symptoms occur. Our data also suggest that blood-borne viruses are a common cause of death (5%) but a rare cause of hospitalisation (\<1%). This may partly relate to coding practices, as the primary cause of hospitalisation for patients with viral hepatitis or HIV may be listed as something else, such as liver disease or an AIDS-defining illnesses.

The pattern of causes of morbidity and mortality is related to age. In older cohorts of people who use illicit drugs, non-communicable diseases cause larger proportions of deaths ([@bib0020]) and relative mortality risks reduce as the reference rates in the general population increase. There may also be secular changes. For example, in cohorts of people who use heroin in Sweden ([@bib0055]) and the UK ([@bib0070]) recruited in the 1960s and 70 s and followed-up until the 1990s, more than half of deaths were drug-related. These higher proportions of drug-related mortality may relate to more limited harm reduction services, which were rolled-out in the 1980s and 90 s in many high-income countries. There is some evidence that the average age of people seeking treatment for heroin dependence is increasing ([@bib0090]) and the importance of non-communicable diseases is also likely to increase.

Interventions designed to improve the health of people who use heroin have focused on prevention and treatment of blood-borne viral infections and overdoses, as well as reduction in drug-related crime. Needle and syringe programmes, take-home naloxone and opiate substitution are well-researched and effective interventions that target these outcomes ([@bib0010]; [@bib0025]; [@bib0085]). However, there are few interventions that aim to prevent and treat common non-communicable diseases in this group. Our results demonstrate the urgent need for research in this area.
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The following is Supplementary data to this article:
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